Malcolm Barratt-Johnson
Direttore Tecnico/Scientifico/R&S presso ALBERT LABS INTERNATIONAL CORP.
Patrimonio netto: - $ in data 30/04/2024
Posizioni attive di Malcolm Barratt-Johnson
Società | Posizione | Inizio | Fine |
---|---|---|---|
ALBERT LABS INTERNATIONAL CORP. | Direttore Tecnico/Scientifico/R&S | - | - |
NovaBiotics Ltd.
NovaBiotics Ltd. Pharmaceuticals: MajorHealth Technology NovaBiotics Ltd. operates as a clinical-stage biotechnology firm. It designs and develops antifungal and antibacterial therapeutics for medically unmet fungal, bacterial, and polymicrobial conditions. It offers clinical and preclinical product candidates to treat clinically challenging infections that include NP213 (Novexatin) phase IIb-ready potent topical treatment for fungal nail infections (onychomycosis); NM001 (Lynovex), a dual antibacterial-mucolytic orphan drug candidate in phase IIa clinical evaluation for cystic fibrosis; NP339 (Novamycin), an antifungal peptide agent against Candida spp and other clinically relevant yeasts/moulds; and NP432 (Novarifyn), a peptide antibacterial candidate for multi-drug resistant gram-negative and gram-positive infections. The company was founded by Deborah A. O?Neil in August 2004 and is headquartered in Aberdeen, the United Kingdom. | Direttore/Membro del Consiglio | 01/10/2020 | - |
Storia della carriera di Malcolm Barratt-Johnson
Statistiche
Distribuzione geografica
Canada | 2 |
Regno Unito | 2 |
Posizioni
Chief Tech/Sci/R&D Officer | 1 |
Director/Board Member | 1 |
Settori
Health Technology | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
ALBERT LABS INTERNATIONAL CORP. | Health Technology |
Aziende private | 1 |
---|---|
NovaBiotics Ltd.
NovaBiotics Ltd. Pharmaceuticals: MajorHealth Technology NovaBiotics Ltd. operates as a clinical-stage biotechnology firm. It designs and develops antifungal and antibacterial therapeutics for medically unmet fungal, bacterial, and polymicrobial conditions. It offers clinical and preclinical product candidates to treat clinically challenging infections that include NP213 (Novexatin) phase IIb-ready potent topical treatment for fungal nail infections (onychomycosis); NM001 (Lynovex), a dual antibacterial-mucolytic orphan drug candidate in phase IIa clinical evaluation for cystic fibrosis; NP339 (Novamycin), an antifungal peptide agent against Candida spp and other clinically relevant yeasts/moulds; and NP432 (Novarifyn), a peptide antibacterial candidate for multi-drug resistant gram-negative and gram-positive infections. The company was founded by Deborah A. O?Neil in August 2004 and is headquartered in Aberdeen, the United Kingdom. | Health Technology |